Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Meridian Bioscience Inc. (VIVO : NSDQ)
 
 • Company Description   
Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis.

Number of Employees: 560

 
 • Price / Volume Information   
Yesterday's Closing Price: $25.37 Daily Weekly Monthly
20 Day Moving Average: 329,294 shares
Shares Outstanding: 43.58 (millions)
Market Capitalization: $1,105.50 (millions)
Beta: 0.34
52 Week High: $28.72
52 Week Low: $17.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.37% 1.08%
12 Week 3.89% 9.38%
Year To Date 24.36% 44.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3471 RIVER HILLS DRIVE
-
CINCINNATI,OH 45244
USA
ph: 513-271-3700
fax: 513-271-3762
None http://www.meridianbioscience.com
 
 • General Corporate Information   
Officers
Jack Kenny - Chief Executive Officer and Director
David C. Phillips - Chairman
Bryan T. Baldasare - Executive Vice President; Chief Financial Officer
James M. Anderson - Director
Anthony P. Bihl III - Director

Peer Information
Meridian Bioscience Inc. (BJCT)
Meridian Bioscience Inc. (CADMQ)
Meridian Bioscience Inc. (APNO)
Meridian Bioscience Inc. (UPDC)
Meridian Bioscience Inc. (IMTIQ)
Meridian Bioscience Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 589584101
SIC: 2835
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 43.58
Most Recent Split Date: 5.00 (1.50:1)
Beta: 0.34
Market Capitalization: $1,105.50 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.44 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: -0.28
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 17.62
Trailing 12 Months: 17.38
PEG Ratio: -
Price Ratios
Price/Book: 2.95
Price/Cash Flow: 12.44
Price / Sales: 3.26
EPS Growth
vs. Year Ago Period: 17.86%
vs. Previous Quarter: 88.57%
Sales Growth
vs. Year Ago Period: 30.45%
vs. Previous Quarter: 25.91%
ROE
03/31/22 - 18.79
12/31/21 - 18.45
09/30/21 - 23.61
ROA
03/31/22 - 14.09
12/31/21 - 13.42
09/30/21 - 16.63
Current Ratio
03/31/22 - 3.85
12/31/21 - 4.08
09/30/21 - 4.09
Quick Ratio
03/31/22 - 2.60
12/31/21 - 2.59
09/30/21 - 2.46
Operating Margin
03/31/22 - 18.97
12/31/21 - 19.21
09/30/21 - 23.00
Net Margin
03/31/22 - 18.34
12/31/21 - 19.14
09/30/21 - 22.46
Pre-Tax Margin
03/31/22 - 23.41
12/31/21 - 24.24
09/30/21 - 28.45
Book Value
03/31/22 - 8.60
12/31/21 - 7.96
09/30/21 - 7.57
Inventory Turnover
03/31/22 - 1.90
12/31/21 - 1.69
09/30/21 - 1.62
Debt-to-Equity
03/31/22 - 0.07
12/31/21 - 0.14
09/30/21 - 0.18
Debt-to-Capital
03/31/22 - 6.26
12/31/21 - 12.65
09/30/21 - 15.45
 

Powered by Zacks Investment Research ©